295.30

1.83% -5.49

After Hours: 295.30

Bio Rad Laboratories Inc (BIO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Bio Rad Laboratories Inc stock is traded at $295.30, with a volume of 308.94K. It is down -1.83% in the last 24 hours and down -5.50% over the past month. Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Previous Close:

$300.79

Open:

$300

24h Volume:

308.94K

Relative Volume:

0.82

Market Cap:

$7.90B

Revenue:

$2.59B

Net Income/Loss:

$168.80M

P/E Ratio:

48.61

EPS:

6.0748

Net Cash Flow:

$357.20M

1W Performance:

+5.05%

1M Performance:

-5.50%

6M Performance:

-2.78%

1Y Performance:

+21.03%

1-Day Range:

$294.07

$301.27

1-Week Range:

$270.00

$305.00

52-Week Range:

$236.73

$343.12

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Name

Bio Rad Laboratories Inc

Sector

Healthcare (1096)

Industry

Medical Devices (139)

Phone

(510) 724-7000

Address

1000 ALFRED NOBEL DRIVE, HERCULES

Employee

7,450

Twitter

@BioRadLifeSci

Next Earnings Date

2026-07-30

Latest SEC Filings

BIO's Discussions on Twitter

Compare BIO vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIO Bio Rad Laboratories Inc	295.30	8.05B	2.59B	168.80M	357.20M	6.0748
ABT Abbott Laboratories	92.71	163.94B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	330.52	127.55B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	80.93	103.66B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	43.48	65.74B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	91.18	52.27B	6.30B	1.07B	1.09B	1.8406

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Downgrade	Citigroup	Buy → Neutral
Oct-01-24	Upgrade	Citigroup	Neutral → Buy
Aug-28-24	Initiated	Wells Fargo	Equal Weight
Jun-03-24	Resumed	Jefferies	Hold
Apr-03-24	Downgrade	Citigroup	Buy → Neutral
Dec-07-23	Initiated	UBS	Buy
Jun-16-23	Initiated	Wells Fargo	Overweight
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Aug-25-22	Initiated	Credit Suisse	Outperform
Jan-28-22	Reiterated	Citigroup	Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-17-18	Initiated	Goldman	Buy
Sep-20-18	Initiated	Morgan Stanley	Equal-Weight
Feb-16-18	Downgrade	CL King	Buy → Neutral
Jul-13-17	Initiated	Wells Fargo	Outperform
Jun-28-17	Upgrade	Deutsche Bank	Hold → Buy
Jan-18-17	Initiated	Deutsche Bank	Hold
Oct-13-16	Initiated	CL King	Buy
May-06-15	Reiterated	Jefferies	Buy
Dec-18-09	Initiated	Maxim Group	Buy
Nov-06-09	Initiated	Jefferies & Co	Buy
Jul-17-09	Initiated	Soleil	Buy
Sep-26-07	Initiated	Banc of America Sec	Buy
Feb-23-07	Downgrade	Robert W. Baird	Outperform → Neutral

View All

Bio Rad Laboratories Inc Stock (BIO) Latest News

Jun 28, 2026

Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.

Jun 28, 2026

Jun 27, 2026

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView

Jun 27, 2026

Jun 26, 2026

Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW) - TradingView

Jun 26, 2026

Jun 25, 2026

Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus

Jun 25, 2026

Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative

Jun 25, 2026

Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart.com

Jun 25, 2026

Jun 24, 2026

Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com

Jun 24, 2026